Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$0.82 - $1.32 $7,214 - $11,613
-8,798 Reduced 48.52%
9,336 $9,000
Q4 2022

Feb 08, 2023

BUY
$0.64 - $1.31 $11,288 - $23,105
17,638 Added 3556.05%
18,134 $15,000
Q3 2022

Nov 10, 2022

SELL
$0.8 - $1.65 $83,751 - $172,736
-104,689 Reduced 99.53%
496 $1,000
Q2 2022

Aug 10, 2022

BUY
$0.56 - $3.25 $57,861 - $335,803
103,324 Added 5552.07%
105,185 $91,000
Q1 2022

May 16, 2022

BUY
$2.46 - $5.92 $2,656 - $6,393
1,080 Added 138.28%
1,861 $6,000
Q4 2021

Feb 14, 2022

BUY
$4.26 - $23.33 $1,473 - $8,072
346 Added 79.54%
781 $4,000
Q3 2021

Nov 15, 2021

BUY
$18.12 - $28.5 $7,882 - $12,397
435 New
435 $11,000

Others Institutions Holding CNTB

About Connect Biopharma Holdings Ltd


  • Ticker CNTB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,015,800
  • Market Cap $55.6M
  • Description
  • Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for t...
More about CNTB
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.